BTG Pactual Asset Management US’s Blueprint Medicines BPMC Stock Holding History

BTG Pactual Asset Management US’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,000	Closed	-$641K	–	256
2025 Q2	$641K	Buy	+5,000	New	+$519K	0.07%	127

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BTG Pactual Asset Management US's BPMC Position: Q3 2025 in Review

BTG Pactual Asset Management US sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,000 shares — an estimated $641K sold.

BTG Pactual Asset Management US first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $641K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

BTG Pactual Asset Management US reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
BTG Pactual Asset Management US sold 5,000 Blueprint Medicines shares in Q3 2025, an estimated $641K.
BTG Pactual Asset Management US first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
BTG Pactual Asset Management US's Blueprint Medicines position peaked at $641K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on BTG Pactual Asset Management US's 13F filing for Q3 2025, filed 13 Nov 2025.